Drugs / ADERAMASTAT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03304964 | Jul 2017 → Jun 2018 | — | Foresee Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02238834 | Jun 2015 → Dec 2018 | — | Foresee Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04750278 | Apr 2021 → Apr 2022 | acute respiratory distress syndrome | Foresee Pharmaceuticals Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03858686 Comparator | Jul 2018 → Dec 2022 | asthma | Foresee Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-09-11 | Foresee Pharmaceuticals Co., Ltd. | Results Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023 foreseepharma.com ↗
The primary Endpoint of LAR (FEV1 AUC-3-8) was met, which suggests that FP-025 (aderamastat) demonstrates clinically meaningful protection against allergen-induced asthma |
| 2023-04-04 | Foresee Pharmaceuticals Co., Ltd. | Results Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial foreseepharma.com ↗
Foresee Pharmaceuticals (6576.TWO), (“Foresee”) announced today the primary endpoint data of FP-025, an oral MMP-12 inhibitor, in an allergic asthma Phase 2a proof-of-concept (POC) trial, in a press conference at Taipei Exchange. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-11 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023 foreseepharma.com ↗ |
| 2023-07-25 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023 foreseepharma.com ↗ |
| 2023-04-04 | Foresee Pharmaceuticals Co., Ltd. | Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial foreseepharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADERAMASTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314499 ↗ |
| Known as | FP-025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04750278 ↗ |
| Action | Inhibit | “FP-025, a novel, highly selective oral matrix metalloproteinase-12 inhibitor” PMID 33331980 ↗ Dec 2020 |
| Modality | Small molecule | — CHEMBL5314499 ↗ |
| Route | Oral | “The study drug will be orally taken as capsules.” NCT02238834 ↗ |
| Target | MMP12 | “The MMP-12 inhibitor FP-025” NCT03304964 ↗ |